The book is intended to be a resource for students as well as scientists in education and for the general public to learn about proteomics and genomics. Chromosomes form the basis for our genetic heritage and are the code for protein synthesis. The Human Genome Map came out in 2002, and the Proteome Sequence Map is under currently being created by a global consortia initiative. Proteome and genome building blocks already form the basis of scientific research areas as well as large parts of the pharmaceutical and biomedical industry. The book initiative will provide the background to and our current understanding of these gene and protein areas, as well as describe how cutting-edge science is using these resources to develop new medicines and new diagnostics for patient care and treatment. The book will be useful for undergraduate students as well as university students and researchers who need a good understanding of genomics and proteomics within the clinical field. The book will also be targeted at a broad public as well as readers not specialized within this field. Dr. Marko-Varga is the head of the Head of Div. Clinical Protein Science & Imaging at the Biomedical Center, Dept. of Measurement Technology and Industrial Electrical Engineering, Lund University, and Professor at the 1st Department of Surgery, Tokyo Medical University, Tokyo, Japan.

While the sequence of the human genome sequence has hit the headlines, extensive exploitation of this for practical applications is still to come. Genomic and post-genomic technologies applied to viral and bacterial pathogens, which are almost equally important from a scientific perspective, have the potential to be translated into useful products and processes much more rapidly. Genomics, Proteomics and Vaccines introduces the history of vaccinology and discusses how vaccines are expected to evolve in the future. It describes the relevant technologies, including genome sequencing and analysis, DNA microarrays, 2D electrophoresis and 2D chromatography, mass spectrometry and high-throughput protein expression and purification. The book also features examples of the exploitation of genomics and post-genomics in vaccine discovery, and contains useful descriptions of the biology and pathogenesis of clinically important bacterial pathogens. This book should be of interest to all those working in vaccine discovery and development in pharmaceutical and biotechnology companies as well as in academic institutions

Technologies collectively called omics enable simultaneous measurement of an enormous number of biomolecules; for example, genomics investigates thousands of DNA sequences, and proteomics examines large numbers of proteins. Scientists are using these technologies to develop innovative tests to detect disease and to predict a patient's likelihood of responding to specific drugs. Following a recent case involving premature use of omics-based tests in cancer clinical trials at Duke University, the NCI requested that the IOM establish a committee to recommend ways to strengthen omics-based test development and evaluation. This report identifies best practices to enhance development, evaluation, and translation of omics-based tests while simultaneously reinforcing steps to ensure that these tests are appropriately assessed for scientific validity before they are used to guide patient treatment in clinical trials.

Comparative Genomics and Proteomics in Drug Discovery gives an overview of how emerging genomic and proteomic technologies are making significant contributions to global drug discovery programs, and in particular the key role that comparative genomics and proteomics play within this strategy. Each chapter is written by respected authorities, with hands-on experience, from both academic and pharmaceutical backgrounds.

Since the publication of the pioneering first edition of Chemical Genomics and Proteomics more than seven years ago, the area of chemical genomics has rapidly expanded and diversified to numerous novel methods and subdisciplines, such as chemical glycomics and lipidomics. This second edition has been updated to uniquely reflect this interdisciplinary feature as well as the remarkable developments that have occurred. The new edition also covers innovative applications from cell biology to drug discovery to, more recently, clinical diagnostics and medical practice, which utilize the concepts of chemical genomics. The text provides an overview of the strategies and methodologies of chemical genomics, focusing on emerging technologies and recent applications in the areas of combination chemical genetics, toxicogenomics, drug chemical genomics and proteomics, and orthogonal chemical genetics. It describes the development and application of novel analytical methods used in lipodomics, such as steroidomics. The book also discusses biomarker discovery applications of microarray technologies using DNA, RNA, and protein and glycan arrays. Chapters cover further applications of biomolecular biomarkers for disease diagnosis, in small molecule drug R&D, and during therapeutic use of medicines. These include prognostic, disease specific, response (surrogate), and toxicity biomarkers. In addition, the text explores the principles of contemporary systems biology and genomics in experimental medicine—a new paradigm that demonstrates a network-oriented view and advanced statistical and informatics data management, opening the way toward personalized medicine. Finally, various in silico chemogenomics approaches are addressed for predicting binding of drug candidates to undesirable targets, which would help in designing better clinical candidates with fewer side effects. This new edition benefits a broad range of readers from industrial and academic researchers in drug discovery, medicinal chemistry, and molecular and cell biology to physicians in clinical diagnostics and students in related fields of study.

The number of new drug approvals has remained reasonably steady for the past 50 years at around 20 to 30 per year, while at the same time the total spending on health-related research and development has tripled since 1990. There are many suspected causes for this trend, including increases in regulatory barriers, the rising costs of scientific inquiry, a decrease in research and development efficiency, the downstream effects of patient expirations on investment, and the lack of production models that have successfully incorporated new technology. Regardless, this trajectory is not economically sustainable for the businesses involved, and, in response, many companies are turning toward collaborative models of drug development, whether with other industrial firms, academia, or government. Introducing greater efficiency and knowledge into these new models and aligning incentives among participants may help to reverse the trends highlighted above, while producing more effective drugs in the process. Genome-Based Therapeutics explains that new technologies have the potential to open up avenues of development and to identify new drug targets to pursue. Specifically, improved validation of gene-disease associations through genomics research has the potential to revolutionize drug production and lower development costs. Genetic information has helped developers by increasing their understanding of the mechanisms of disease as well as individual patients' reactions to their medications. There is a need to identify the success factors for the various models that are being developed, whether they are industry-led, academia-led, or collaborations between the two. Genome-Based Therapeutics summarizes a workshop that was held on March 21, 2012, titled New Paradigms in Drug Discovery: How Genomic Data Are Being Used to Revolutionize the Drug Discovery and Development Process. At this workshop the goal was to examine the general approaches being used to apply successes achieved so far, and the challenges ahead.

Gazing into crystal balls is beyond the expertise of most scientists. Yet, as we look further into the 21st century, one does not have to be Nostradamus to predict that the current genomics and proteomics "revolution" will have an immense impact on medical bacteriology. This impact is already being re- ized in many academic departments, and although encroachment on routine diagnostic bacteriology, particularly in the hospital setting, is likely to occur at a slower pace, it remains nonetheless inevitable. Therefore, it is important that no one working in bacteriology should find themselves distanced from these fundamental developments. The involvement of all clinical bacteriologists is essential if the significant achievements of genome sequencing and analysis are to be turned into tangible advances, with resulting benefits for patient care and m- agement. It is our hope that Genomics, Proteomics, and Clinical Bacteriology: Methods and Reviews will play a part in bringing such a development to fruition. The advances in genomics and proteomics have already given us frequent opportunities to reassess our knowledge and understanding of established b- terial adversaries, and have provided us with the means to identify new foes. The new knowledge gained is enabling us to reconsider, for example, our c- cepts of bacterial pathogenicity, phylogeny and novel targets for antibacterial chemotherapy. These topics, and others, are considered in Genomics, Proteomics, and Clinical Bacteriology: Methods and Reviews.